Invention Grant
US08119129B2 Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
有权
抗CTLA4抗体与多种治疗方案的组合，用于增殖性疾病的协同治疗
- Patent Title: Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
- Patent Title (中): 抗CTLA4抗体与多种治疗方案的组合，用于增殖性疾病的协同治疗
-
Application No.: US12462168Application Date: 2009-07-30
-
Publication No.: US08119129B2Publication Date: 2012-02-21
- Inventor: Maria Jure-Kunkel , Francis Y. Lee
- Applicant: Maria Jure-Kunkel , Francis Y. Lee
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Stephen C. D'Amico
- Main IPC: A61K39/395
- IPC: A61K39/395
Abstract:
Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Public/Granted literature
- US20100098701A1 Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases Public/Granted day:2010-04-22
Information query
